List of Vaccines Companies in Netherlands - 12

Batavia Biosciences is a science-based CDMO that offers personalized services that fully support all the stages of biopharmaceutical development, from cloning to GMP manufacture and release of clinical material for phase I/II studies. We are not your standard CDMO - our customers regularly refer to us as their product development partner and thought partner. We focus on the early stages of product development with services ranging from DNA cloning, mammalian cell line generation, upstream process development, purification development, product characterization to clinical manufacturing. Headquartered in Leiden, The Netherlands, Batavia Biosciences is privileged to have strong strategic partners in both the EU and US. Batavia Biosciences aims to significantly contribute to ease human suffering from infectious disease and cancer.

Bilthoven Biologicals is a biopharmaceutical company which produces Inactivated Polio Vaccines (IPV), Tetanus Vaccines, Diphtheria-Tetanus-Polio Vaccines (DT-PV) and Bacillus Calmette-Guérin (BCG) for the treatment of bladder cancer. We deliver our vaccines to UNICEF, with which we support the World Health Organisation (WHO) to eradicate polio. Bilthoven Biologicals has been part of the Cyrus Poonawalla Group since 2012, the world’s largest vaccine producer and employs more than 500 employees.

Cimaas - Our mission is achieving a better cure for cancer. For this, CiMaas develops therapies engaging the immune system for the treatment of a steadily growing population facing cancer that cannot be cured by the current standard of care. A better cure relates to safe technology taking away several of the severe side-effects of current therapies.

CimCure’s solution is a vaccination based immunotherapy directed to the tumor blood vessels that are common to most solid tumors.

CyTuVax develops therapeutic vaccines against cancer and protective vaccines against viral & bacterial pathogens for which there is a high medical need. The patient is at the core in our vaccine development in which we apply our powerful adjuvant platform technology.

Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies. As an established independent CDMO in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans. Part of Utrecht Science Park Bilthoven

ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. SLP®immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP®lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810, Libtayo®), a PD-1 (programmed cell death protein 1) antibody in development by Regeneron, which was recently approved by the FDA as monotherapy for patients with advanced cutaneous squamous cell carcinoma. ISA develops a diverse SLP®immunotherapy portfolio targeting unmet medical needs in cancer and chronic infections, including tailored therapy for rare diseases. ISA´s most advanced clinical-stage immunotherapeutic is ISA101, an SLP® immunotherapy targeting human papillomavirus (HPV)-induced diseases. It is currently in clinical development in advanced and recurrent cervical cancer, incurable HPV16-postive solid tumors and anal intraepithelial neoplasia (AIN). Clinical proof-of-concept has been established in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV. The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com SLP® and AMPLIVANT® are registered trademarks in Europe.

Pantarhei Bioscience BV (PRB) is a company in The Netherlands with an innovative concept of drug development in Woman’s Health. PRB's wholly owned subsidiary company – Pantarhei Oncology (PRO) (http://www.pantarheioncology.nl) develops innovative treatments for Endocrine Cancer. PRB and PRO have developed a product pipeline based on the proven ability to identify novel medical uses of existing molecules, drugs, hormones, biologicals and combinations thereof in these areas of medicine. The main areas of expertise of PRB are reproductive hormone related treatments such as contraception and menopausal hormone therapy (MHT). The main areas of expertise of PRO are and in oncology breast cancer, prostate cancer and ovarian cancer. The business concept of PRB and PRO is to develop the patented new treatment concepts up to proof-of-concept (PoC) in the human (phase II). Using existing molecules often provides first evidence of safety. The business model is based on solid patent protection, internal project management and external research and development activities. Intellectual property (IP) and data supporting the new treatment concepts are licensed out for completion of clinical development (phase III), regulatory approval and sales and marketing by a licensee/partner.

ProteoNic is a biotechnology company active in development and licensing of DNA technology for cell line generation and recombinant protein production for pharmaceutical applications. We offer premium vector technology that substantially boosts production levels of therapeutic proteins and other biologics. Cost savings are immediate and sizeable, freeing up production capacity and enabling commercially viable production of difficult to express proteins. ProteoNic's 2G UNic™ drives higher production for all types of therapeutic protein products, including monoclonal antibodies, biosimilars and more difficult-to-express (DTE) proteins, such as Fc-fusion proteins and bi-specifics, contributing to their economic viability. Our patented technology does not require modifications to existing production systems or work flows and is compatible with all production cell lines and expression systems used in the industry. Independent technical and commercial validation by third parties, including top tier biopharma, demonstrates severalfold productivity level increases that translate into multi-million Euros in annual cost savings. The technology has wide ranging potential to boost production efficiencies in other important applications, including viral vector production, protein production in yeast and technologies which impact product quality. The company is headquartered at the BioScience Park in Leiden, the Netherlands and has a Boston, USA office for Business Development in the North American market.

Uneedle realises a proprietary microneedle platform "Bella-mu" and "Bella-Vue", co-developing intradermal & suprachoroidal administered medicinal products with pharmaceutical partners. Uneedle is the legal manufacturer of this superior - short lumen - delivery platform. The single, hollow "Uneedles" are FDA approved and CE marked for direct application in the clinics worldwide.

ViroNovative BV, established in 2002, is dedicated to providing a complete solution to human Metapneumovirus (hMPV), a virus discovered in 2001 at the Department of Viroscience, Erasmus MC. To this end, ViroNovative is co-developing diagnostics, vaccines, antibodies and antivirals for the detection, prevention and treatment of hMPV infection. With a strong network of industrial partners (to date 20 licenses on the hMPV patents are active) we generate new products and economic value.

Wageningen University & Research provides education and generates knowledge in the domain of healthy food and living environment. ‘To explore the potential of nature to improve the quality of life'. That is the mission of Wageningen University & Research (WUR). A staff of 6,500 and 10,000 students from over 100 countries work everywhere around the world in the domain of healthy food and living environment for governments and the business community-at-large. The strength of WUR lies in its ability to join the forces of specialised research institutes and the University. It also lies in the combined efforts of the various fields of natural and social sciences. This union of expertise leads to scientific breakthroughs that can quickly be put into practice and be incorporated into education. This is the Wageningen Approach. The scientific quality of WUR is affirmed by the prominent position we occupy in international rankings and citation indexes.